AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8036464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68308
Study 2713513 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, adjusted loco-regional treatment (surgery and/or radiotherapy) and adjuvant chemotherapy with or without immunostimulation
Number of subjects: 279
Study 2713513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonotherapy for tumoral reduction
Number of subjects: 279
Study 1094562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (Ciba‐SU13437)
Number of subjects: 19
Study 1094562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 19
Study 1094562 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clofibrate and cholestyramine
Number of subjects: 19
Study 1094562 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 19
Study 30883047 — intervention group
Group type: EXPERIMENTAL
Intervention: PB2452
Number of subjects: 64
Study 30883047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27566993 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 560
Study 27566993 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction intervention
Number of subjects: 560
Study 27566993 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 560
Study 24227448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 23
Study 24227448 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 23
Study 23782510 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (12 weeks of physical exercise and psycho-educational intervention with five consultations)
Number of subjects: 210
Study 23782510 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 23782510 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 210
Study 21315206 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access for coronary angiography/intervention
Number of subjects: 7021
Study 21315206 — intervention group
Group type: COMPARATOR
Intervention: Femoral access for coronary angiography/intervention
Number of subjects: 7021
Study 19059545 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception counseling (PCC)
Number of subjects: 633
Study 19059545 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 633
Study 17852628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1072 nm light treatment for a period of between 6 and 8 weeks
Number of subjects: 0
Study 15082593 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane covered stent (n = 57)
Number of subjects: 112
Study 15082593 — intervention group
Group type: COMPARATOR
Intervention: Original diamond stent (n = 55)
Number of subjects: 112
Study 11679859 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prochlorperazine administered intravenously by means of 2‐minute push (bolus group)
Number of subjects: 99
Study 11679859 — intervention group
Group type: COMPARATOR
Intervention: 10 mg prochlorperazine diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15‐minute period (infusion group)
Number of subjects: 99
Study 11679859 — intervention group
Group type: COMPARATOR
Intervention: Bolus group
Number of subjects: 99
Study 11679859 — intervention group
Group type: COMPARATOR
Intervention: Infusion group
Number of subjects: 99
Study 9175991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (mean urinary Na excretion 61 mmol/24 h)
Number of subjects: 94
Study 9175991 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean urinary Na excretion 142 mmol/24 h)
Number of subjects: 94
Study 8200248 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Lupron Depot 3.75 mg for one month, then daily subcutaneous dose increased from 0.5 mg to 1.0-1.5 mg)
Number of subjects: 28
Study 8200248 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (maximum therapeutic dosage)
Number of subjects: 28
Study 2828072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide (350 mg/m2/day for 5 days) and cisplatin (40 mg/m2/day for 5 days)
Number of subjects: 12
Study 2828072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose etoposide (350 mg/m2/day for 5 days)
Number of subjects: 12
Study 30824430 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative Writing Workshops (CWW) - 4 sessions of 2 hours each over 4 weeks
Number of subjects: 16
Study 30824430 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) - no participation in CWW
Number of subjects: 16
Study 31005942 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) screening
Number of subjects: 5500
Study 31005942 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based phototherapy
Number of subjects: 5500
Study 28547955 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 100
Study 28547955 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 100
Study 25880483 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed (yes)
Number of subjects: 4335
Study 25880483 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (no)
Number of subjects: 4335
Study 23635621 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-directed sessions in a simulation laboratory
Number of subjects: 116
Study 23635621 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching (no simulation)
Number of subjects: 116
Study 23635621 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation group
Number of subjects: 116
Study 21898419 — intervention group
Group type: EXPERIMENTAL
Intervention: Medialization laryngoplasty (ML)
Number of subjects: 24
Study 21898419 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal reinnervation (LR)
Number of subjects: 24
Study 21898419 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 19187377 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sutures
Number of subjects: 445
Study 19187377 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 445
Study 16960414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg kg(‐1) IV)
Number of subjects: 44
Study 16960414 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (7% in O(2) at 6L min(‐1) for 2 minutes)
Number of subjects: 44
Study 15082207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10mg (flexible dosing allowed: 5mg, 10mg, or 20mg)
Number of subjects: 323
Study 15082207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 323
Study 11174341 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone bolus followed by continuous infusion (n = 9)
Number of subjects: 19
Study 11174341 — intervention group
Group type: COMPARATOR
Intervention: Placebo bolus followed by continuous milrinone infusion (n = 10)
Number of subjects: 19
Study 9508162 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) alone
Number of subjects: 1740
Study 9508162 — intervention group
Group type: COMPARATOR
Intervention: Combined modality treatment (CT + RT)
Number of subjects: 1740
Study 9508162 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional RT after CT
Number of subjects: 1740
Study 9508162 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 1740
Study 9508162 — intervention group
Group type: COMPARATOR
Intervention: No RT
Number of subjects: 1740
Study 8165955 — intervention group
Group type: EXPERIMENTAL
Intervention: New Marburg rehabilitation concept (group A) - additional twice a week exercise in a fitness center under medical supervision
Number of subjects: 40
Study 8165955 — intervention group
Group type: COMPARATOR
Intervention: Out-patient physiotherapy only (group B)
Number of subjects: 40
Study 3073463 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (small repeated doses)
Number of subjects: 30
Study 3073463 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (large single dose)
Number of subjects: 30
Study 3073463 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study 3073463 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase and Heparin
Number of subjects: 30
Study 3073463 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 30
Study 30879076 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically negligible RKF
Number of subjects: 1280
Study 30879076 — intervention group
Group type: COMPARATOR
Intervention: Higher dialysis dose (spKt/Vurea 1.7)
Number of subjects: 1280
Study 30879076 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved RKF at 1-year follow-up
Number of subjects: 1280
Study 31335651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (titrated to maximum dose 600 mg per day)
Number of subjects: 26
Study 31335651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31335651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (in post hoc analysis for patients with CIPN caused by oxaliplatin)
Number of subjects: 26
Study 31335651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in post hoc analysis for patients with CIPN caused by oxaliplatin)
Number of subjects: 26
Study 29164923 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional tongue depressors
Number of subjects: 92
Study 29164923 — intervention group
Group type: COMPARATOR
Intervention: Flavored tongue depressors
Number of subjects: 92
Study 26625980 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth assisted healthy lifestyle intervention package including motivational counseling, low GI nutritional advice, daily physical activity prescription, and smartphone app support
Number of subjects: 253
Study 26625980 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care
Number of subjects: 253
Study 24448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracycline for children younger than 6 months and oral azithromycin for those 6 months and older (annual MDA)
Number of subjects: 13
Study 24448262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA)
Number of subjects: 13
Study 24448262 — intervention group
Group type: COMPARATOR
Intervention: One additional MDA
Number of subjects: 13
Study 22241792 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent lenalidomide with pneumococcal 7-valent conjugate vaccine (PCV) in Cohort B (both vaccinations while on lenalidomide)
Number of subjects: 0
Study 22241792 — intervention group
Group type: COMPARATOR
Intervention: Single-agent lenalidomide with pneumococcal 7-valent conjugate vaccine (PCV) in Cohort A (first vaccination prior to lenalidomide, second while on lenalidomide)
Number of subjects: 0
Study 22241792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical myeloma response
Number of subjects: 0
Study 20630093 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom made neck jig device
Number of subjects: 5
Study 17669103 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii
Number of subjects: 124
Study 17669103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 15521079 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 ml normal saline intravenously for 24 h before drainage
Number of subjects: 49
Study 15521079 — intervention group
Group type: COMPARATOR
Intervention: No saline infusion (control group)
Number of subjects: 49
Study 11981147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine (doses greater than or equal to 1.37 microg.kg-1.min-1)
Number of subjects: 0
Study 11981147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 0
Study 9442774 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 276
Study 9442774 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 276
Study 7884257 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100-300 mg/day for seven days before operation)
Number of subjects: 20
Study 7884257 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 2224784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimen A1 (cyclophosphamide 1200 mg/m2, vincristine 1.5 mg/m2, pyrarubicin 40 mg/m2, cisplatin 90 mg/m2) followed by bone marrow transplantation (BMT)
Number of subjects: 109
Study 2224784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) after complete remission
Number of subjects: 109
Study 2224784 — intervention group
Group type: COMPARATOR
Intervention: Alternating treatment by regimen B (cyclophosphamide and ACNU) and intensified regimen A1
Number of subjects: 109
Study 2224784 — intervention group
Group type: COMPARATOR
Intervention: Alternating administration of regimen C (cyclophosphamide and DTIC) and intensified A1
Number of subjects: 109
Study 2224784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive induction chemotherapy
Number of subjects: 109
Study 534065 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% urea (intravenous)
Number of subjects: 90
Study 534065 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol (intravenous)
Number of subjects: 90
Study 534065 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (intravenous)
Number of subjects: 90
Study 534065 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% urea (oral)
Number of subjects: 90
Study 534065 — intervention group
Group type: COMPARATOR
Intervention: 10% glycerol (oral)
Number of subjects: 90
Study 534065 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of thiopental (in conjunction with hyperosmotic agents)
Number of subjects: 90
Study 31599194 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 0
Study 31599194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered allocation
Number of subjects: 0
Study 31599194 — intervention group
Group type: COMPARATOR
Intervention: External patients as controls
Number of subjects: 0
Study 31599194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model
Number of subjects: 0
Study 31599194 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian and frequentist approaches
Number of subjects: 0
Study 31599194 — intervention group
Group type: COMPARATOR
Intervention: Historical dataset
Number of subjects: 0
Study 31599194 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm recruitment plan
Number of subjects: 0
Study 31599194 — intervention group
Group type: EXPERIMENTAL
Intervention: Finalised analysis plan
Number of subjects: 0
Study 29992831 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF 1000 mg once daily
Number of subjects: 87
Study 29992831 — intervention group
Group type: COMPARATOR
Intervention: MPFF 500 mg twice daily
Number of subjects: 87
Study 29020293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with darunavir/ritonavir and lamivudine
Number of subjects: 249
Study 29020293 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with darunavir/ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine
Number of subjects: 249
Study 26169691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-switched Nd:YAG laser treatment
Number of subjects: 32
Study 26169691 — intervention group
Group type: COMPARATOR
Intervention: 532-nm Q-switched Nd:YAG laser treatment
Number of subjects: 32
Study 23427000 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9667 (30-1,800 mg single dose)
Number of subjects: 0
Study 23427000 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9667 (600-2,400 mg QD, 1,200 mg BID, or 600 mg QID for 14 days)
Number of subjects: 0
Study 21111684 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating Dose
Number of subjects: 135
Study 21111684 — intervention group
Group type: COMPARATOR
Intervention: Stable Dose
Number of subjects: 135
Study 21111684 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study 19744761 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite Multibond+Definite
Number of subjects: 24
Study 19744761 — intervention group
Group type: COMPARATOR
Intervention: Syntac+Variolink Ultra
Number of subjects: 24
Study 16925467 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (200 mEq)
Number of subjects: 28
Study 15119920 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 157
Study 15119920 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 157
Study 15119920 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 157
Study 15119920 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 157
Study 11755586 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 0
Study 11755586 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal delivery
Number of subjects: 0
Study 9136940 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2A (Roferon‐A) as a co‐induction agent with intensive combination chemotherapy (PCAB: prednisone 60 mg/m2 days 1‐5, cyclophosphamide 600 mg/m2 day 1, BCNU 30 mg/m2 day 1, doxorubicin 30 mg/m2 day 1, repeated every 28 d for a total of 12 cycles)
Number of subjects: 0
Study 9136940 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2A (Roferon‐A) for patients who achieved plateau phase
Number of subjects: 0
Study 9136940 — intervention group
Group type: COMPARATOR
Intervention: Intensive combination chemotherapy (PCAB) without interferon
Number of subjects: 0
Study 8201815 — intervention group
Group type: EXPERIMENTAL
Intervention: Video projection of humorous movies four times daily for 3 months
Number of subjects: 2
Study 8201815 — intervention group
Group type: COMPARATOR
Intervention: Video projections of other assorted movies at the same rate
Number of subjects: 2
Study 3720035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dialysis (maintaining predialysis blood urea nitrogen below 60 mg/dl and serum creatinine below 5 mg/dl)
Number of subjects: 34
Study 3720035 — intervention group
Group type: COMPARATOR
Intervention: Non-intensive dialysis (maintaining predialysis blood urea nitrogen below 100 mg/dl and serum creatinine below 9 mg/dl)
Number of subjects: 34
Study 28551715 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 24
Study 28551715 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (60 mg)
Number of subjects: 24
Study 28551715 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (600 mg)
Number of subjects: 24
Study 28551715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26860794 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated Tai Chi exercise (40 min, three times a week for 26 weeks)
Number of subjects: 60
Study 26860794 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated Tai Chi exercise
Number of subjects: 60
Study 25004111 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom Immunotherapy (VIT) for 4 months
Number of subjects: 0
Study 25004111 — intervention group
Group type: COMPARATOR
Intervention: Non-allergic healthy controls
Number of subjects: 0
Study 22730857 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-coated CPB
Number of subjects: 40
Study 22730857 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated CPB)
Number of subjects: 40
Study 15911424 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T/3TC/IDV
Number of subjects: 27
Study 15911424 — intervention group
Group type: COMPARATOR
Intervention: AZT/3TC/IDV
Number of subjects: 27
Study 15911424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (d4T/3TC/IDV and AZT/3TC/IDV)
Number of subjects: 27
Study 12394199 — intervention group
Group type: COMPARATOR
Intervention: No salt (control group)
Number of subjects: 38
Study 9987043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 0
Study 7762912 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin at a bolus dose of 2000 U at the initiation of dialysis followed by 1000 U/h during 4-hour hemodialysis sessions
Number of subjects: 13
Study 2407002 — intervention group
Group type: EXPERIMENTAL
Intervention: UW solution
Number of subjects: 257
Study 2407002 — intervention group
Group type: COMPARATOR
Intervention: Euro-Collins solution
Number of subjects: 257
Study 7428411 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg naproxen, 400 mg ibuprofen, and 25 mg indomethacin twice daily with 500 mg naproxen suppository at night
Number of subjects: 30
Study 7428411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen tablet and suppository phase
Number of subjects: 30
Study 7428411 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin capsule and naproxen suppository phase
Number of subjects: 30
Study 7428411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two non-steroidal anti-inflammatory drugs
Number of subjects: 30
Study 7428411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen suppositories
Number of subjects: 30
Study 31769585 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuramis® Volume Lidocaine
Number of subjects: 88
Study 31769585 — intervention group
Group type: COMPARATOR
Intervention: VYC‐20L
Number of subjects: 88
Study 30176883 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Number of subjects: 27
Study 30176883 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Group
Number of subjects: 27
Study 30176883 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 27
Study 26914484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 testing (referral for a vitamin B12 blood test)
Number of subjects: 5131
Study 26914484 — intervention group
Group type: COMPARATOR
Intervention: No vitamin B12 testing (no referral)
Number of subjects: 5131
Study 25306870 — intervention group
Group type: EXPERIMENTAL
Intervention: RetinSphere (topical retinoid combination)
Number of subjects: 30
Study 25306870 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30
Study 23857683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacteria growth indicator tube (MGIT) 960 system
Number of subjects: 0